
Blueprint MedTech Incubator Hub Cycle 7 Funding Solicitation
Posted September 24, 2026
Cimit's Center for Innovative NeuroTech Advancement (CINTA) & NeuroTech Harbor (NTH) announce the Cycle 7 Award Competition supported by the NIH Blueprint MedTech Program.
Cimit’s Center for Innovative NeuroTech Advancement (CINTA) & NeuroTech Harbor (NTH) announce the Cycle 7 Award Solicitation supported by the NIH Blueprint MedTech Program. This program is seeking projects aimed at developing emerging technologies into commercially viable, clinically focused solutions for disorders of the nervous system that are aligned with the mission and interests of the participating NIH institutes and centers.
Overview
This Cycle 7 funding solicitation has changed significantly from Blueprint MedTech funding Cycles 1-5. Potential applicants are encouraged to thoroughly review this page and the associated FAQs.
Innovators developing groundbreaking medical device technologies face several challenges along the translational path from bench to bedside. The NIH Blueprint MedTech: Incubator Hubs aim to address such challenges by accelerating the development of cutting-edge medical devices that will prevent, diagnose, and/or treat disorders involving the nervous system or consequences of such a disease or injury. Examples of within-scope projects include but are not limited to:
• Addressing early and accurate diagnosis or early selection of the most effective therapy.
• Facilitating the deployment of long-term therapy for those with persistent neurologic deficits, including technologies for home-based interventions that address motor, cognitive, and language impairments.
This program will catalyze the translation of novel technologies from proof-of-concept to a prototype ready for first-in-human testing and will provide: (a) non-dilutive funds to support medical device development activities, and (b) ongoing, specialized support from experienced executive mentors. The Hubs can also assist innovators in obtaining additional resources and support services from a pool of vetted providers. These resources and support services can assist on product design, regulatory pathways, reimbursement, intellectual property, commercialization, and strategic partnership issues as well as commercialization plan development, team building, needs assessment, and other translational activities.
The NIH-funded Blueprint MedTech Incubator program will provide funding, mentoring, oversight, and in-kind resources to innovator teams. The objective of Hub support is to further develop and de-risk these groundbreaking technologies to the point of readiness for first-in-human testing (i.e., support concludes prior to any clinical trials evaluating safety or effectiveness in humans). By the conclusion of Blueprint MedTech Incubator funding, it is anticipated that projects will have secured non-governmental funding or be ready to apply for funding for a companion Translator solicitation from NIH (PAR-25-383, “Blueprint Medtech: Translator UG3/UH3 – Clinical Trial Optional” which supports first-in-human evaluations of safety and effectiveness), or other NIH funding sources. Human subjects research other than surveys or user interface studies cannot be supported through this solicitation. For further details about support of human subjects research, please see the FAQs.
Funding Opportunity
There are two stages of funding in the program. The first stage is a 20-week Sprinter award for $100,000 total cost (direct + indirect), aimed at de-risking the project and undertaking the next critical steps towards developing the product. Mentors will work with awardees throughout the Sprinter project to help address risks, complete the selected milestone(s), and prepare for a Deep Dive evaluation, as described below. Outcomes from the Sprinter project and Deep Dive evaluation are used to select which applicants receive an Optimizer award of $1,280,000 total cost (direct + indirect + resources) for one year if funding is available. Optimizer awards are intended to advance the project forward to a prototype ready for first-in-human testing. Optimizer projects are one year with the potential for up to four years of continued funding, depending on performance and availability of funding. In addition to monetary support of Optimizer projects, mentoring resources are provided in-kind, as well as access to vetted subject matter expert (SME) resources and support services necessary for translation. The cost of SME resources and support services are included in the $1,280,000 award. Please see the FAQs. At any point, a project reaching readiness for first-in-human testing may be advised to apply to an NIH Translator solicitation or other sources of funding.
Eligibility
Principal Investigators (PIs) from academic institutions, industry, and nonprofit organizations are invited to apply. Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Principal Investigator(s) is (are) invited to work with their organization to develop and submit a proposal. Per NIH policy, awards made under this solicitation will not include foreign subawards. For additional information, please reference the NIH Policy on Foreign Subawards.
Process
As outlined in the figure below, applicants first submit a pre-proposal. NIH program staff will determine whether the pre-proposal fits within the interests of the participating NIH institutes and centers and is aligned with the scope of the Blueprint MedTech program. Pre-proposals are submitted through the simple online application form and are equivalent to approximately three pages. Applicants are encouraged to gather input from the stakeholder community for the target clinical condition, including patients, to better understand their individual experiences and unmet needs.
Selected pre-proposal applicants will be invited to submit full proposals through the same online application system. The full proposal form is equivalent to approximately ten pages and will undergo review by CINTA and NTH. As part of the review process, applicants are required to participate in a 30-minute interview with reviewers to clarify information submitted in their application. Applicants must prepare a presentation for the interview process and participate in the interview (see Timeline section below for dates).
Reviews of the full application and interviews are used to determine which applications are appropriate for a Sprinter award. Sprinter awards are utilized to address key gaps and risks identified by the applicant and to complete one or more initial milestones in the product development pathway.
Upon successful completion of the Sprinter project, applicants must participate in an interactive “Deep Dive” evaluation, which is the final due diligence stage of review prior to funding decisions on Optimizer projects. Deep Dive evaluations will undergo review by CINTA and NTH. NIH will make the final funding decision.
All reviews and discussions regarding pre-proposals, interviews, full proposals, and deep dives will be conducted on a confidential basis.

The above graphic represents the stages starting from pre-proposal to Optimizer award.
Program Approach
Full proposals will be assessed by CINTA and NTH for the project’s commercial viability, including but not limited to:
- the likelihood of technical de-risking and of achieving a prototype ready for first-in-human testing
- market need
- regulatory pathway
- potential clinical impact
- reducing treatment gaps
- projected costs to the payer
Reviewers are chosen based on their expertise in one or more of these areas and their comments and critiques focus on these aspects. Applications do not receive an overall impact score, and applicants are only provided a brief review summary. Award decisions are made by NIH and issued and managed by the NIH Blueprint MedTech Incubator program.
Timeline
September 24, 2026: Pre-proposal submission opens
UPDATE: One informational webinar will be held on September 29 at 3:00 PM ET. Registration is required. Office hours will be offered by appointment after the webinar. Note: The webinar will be recorded and sent to all registrants after the session.
October 21, 2026: Pre-proposal submission deadline
November 24, 2026: Submission opens for full proposals (by invitation only)
December 21, 2026: Full proposal submission deadline
February 3 – February 23, 2027: Interviews
March – August 2027: Sprinter decisions made and awarded on a rolling basis
Fall 2028: Sprinter period of performance
Spring 2028: Deep Dive Assessment
Fall 2028: Optimizers awarded
Early 2029: Earliest start of Optimizer period of performance
Guidelines
- Pre-proposals must be submitted through the Blueprint MedTech: Incubator Hubs Program online application system. Projects must have demonstrated proof-of-concept with the goal of developing a prototype ready for first-in-human studies.
- A subset of pre-proposals will be invited to submit full applications, which are also submitted through the online proposal submission system. Complete plans must be provided in the application for advancing the technology to a prototype ready for first-in-human testing within five years. Applicants must prepare for and participate in a 30-minute interview. Applicants must make themselves available during assigned time periods (see Timeline).
- The performance period for Sprinters is 20 weeks. Sprinter support consists of $100,000 total costs and mentor support. We expect to make up to 10 Sprinter awards from this solicitation.
- Sprinter funding cannot be used to support animal or human subjects research.
- Following completion of the Sprinter project, applicants will proceed to a “Deep Dive” review that is expected to take approximately six weeks. During this time applicants will need to commit significant effort to work with the Deep Dive team and respond to the team’s inquiries.
- The performance period for Optimizer projects is one year with the potential for up to four additional years of continued funding depending on results from the prior year and availability of funding. Annual Optimizer support consists of no more than $1,280,000 total cost.
- During the Optimizer performance period, human subjects research (other than surveys or user interface studies) cannot be supported through this solicitation. For further details about support of human subjects research, please see the FAQs.
- Sprinter and Optimizer funding cannot be used to pivot away from the technology or clinical indication as stated in the full application, unless prior approval is granted from the NIH.
Application Criteria
CINTA and NTH are seeking proposals leading to commercialization of groundbreaking preventative, therapeutic, and/or diagnostic medical devices. At a minimum, projects must have already clearly demonstrated proof-of-concept at the time of application. The technologies proposed must have a pathway to a prototype ready for first-in-human testing within up to five years of Optimizer funding and have a viable pathway to commercial development. When projects are nearly ready for first-in-human testing, they may be redirected to the companion NIH Blueprint MedTech: Translator NOFO.
Applications must focus on an intended use involving the nervous system or addressing consequences of such a disease or injury in an area of interest of the participating institutes/centers. Since applications outside the mission of these participating institutes/centers will not be invited to submit full proposals, applicants are encouraged to review the website. Direct questions about mission fit to the points of contact listed on the NIH Blueprint MedTech website prior to submitting a pre-proposal and indicate which specific disease is targeted by your product. All other questions should be submitted to info@blueprintneurotech.org.
Applicants must have collaborative teams incorporating product development and clinical expertise. Input from these collaborators must be clearly reflected throughout the applications and proposed scope of work. CINTA and NTH can assist in connecting potential applicants with potential collaborators if requested. Applicants from teams without clinical expertise are strongly encouraged to engage clinical partners prior to submitting a pre-proposal.
Applications should:
- Identify the initial intended use (e.g., Beachhead Market) for the proposed device.
- Clearly define the current state of the art and its limitations and highlight how the proposed technology will advance patient care.
- Include data showing that the proposed technology has already demonstrated proof-of-concept for the targeted indication with enough confidence that the remaining challenges are primarily related to preparations for first-in-human studies.
- Propose medical devices with first-of-its-kind technologies, novel intended use, or new safety aspects (typically De Novo, PMA, or possibly 510(k) requiring clinical data).
- Propose solutions that are affordable and accessible to all clinically relevant communities.
Applications will NOT be considered for:
- Products not regulated by the FDA.
- Fundamental basic/applied research projects that have not yet demonstrated proof-of-concept.
- Device technologies that do not significantly advance the state of the art (e.g., device technology that proposes minor modifications to FDA-approved/cleared medical device technology).
- Animal model development: all in vivo animal models must be well established and characterized, and available to the applicant.
- Technologies for functional augmentation of healthy individuals.
- Projects that are not well-aligned with areas of interest of the NIH participating organizations.
Please click here to sign up for our informational webinar or to schedule time for office hours with program staff.
Please contact info@blueprintneurotech.org if you have any questions about the program.